Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
EDAP TMS SA is a medical devices business based in the US. EDAP TMS shares (EDAP) are listed on the NASDAQ and all prices are listed in US Dollars. EDAP TMS employs 227 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $6.60 |
|---|---|
| 52-week range | $5.00 - $7.88 |
| 50-day moving average | $6.83 |
| 200-day moving average | $6.57 |
| Wall St. target price | $11.21 |
| PE ratio | 330 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.02 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.6 from 2022-07-01
| 1 week (2022-06-28) | -2.22% |
|---|---|
| 1 month (2022-06-03) | -5.31% |
| 3 months (2022-04-05) | -9.47% |
| 6 months (2022-01-05) | 5.60% |
| 1 year (2021-07-02) | -4.35% |
|---|---|
| 2 years (2020-07-02) | 157.82% |
| 3 years (2019-07-05) | 135.71% |
| 5 years (2017-07-05) | 106.25% |
Valuing EDAP TMS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of EDAP TMS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
EDAP TMS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 330x. In other words, EDAP TMS shares trade at around 330x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
EDAP TMS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 90.47. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into EDAP TMS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $46.8 million |
|---|---|
| Gross profit TTM | $18.4 million |
| Return on assets TTM | -1.89% |
| Return on equity TTM | 0.73% |
| Profit margin | 0.61% |
| Book value | $1.52 |
| Market capitalisation | $220.9 million |
TTM: trailing 12 months
We're not expecting EDAP TMS to pay a dividend over the next 12 months.
Over the last 12 months, EDAP TMS's shares have ranged in value from as little as $5 up to $7.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EDAP TMS's is 1.3471. This would suggest that EDAP TMS's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
EDAP TMS S. A. , together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.